Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate
US9708366B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 27, 2012 |
| Grant date | Jul 18, 2017 |
| Priority date | — |
| Expiry date | Jul 24, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/107
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides compounds, compositions and methods for treating Autism Spectrum Disorders (ASD) using glycyl-2-methylprolyl-glutamic acid (G-2-MePE) and analogs thereof. Autism Spectrum Disorders include Autism, Autistic Disorder Asperger Syndrome, Childhood Disintegrative Disorder, Pervasive Developmental Disorder—Not Otherwise Specified (PDD-NOS), Fragile X Syndrome, and Rett Syndrome. Compositions containing compounds include water-soluble formulations, water-in-oil micro-emulsions, water-in-oil coarse emulsions, water-in-oil liquid crystals, nanocapsules, tablets, and orally administered gels. The compounds and compositions of this invention can be administered intravenously, intraventricularly, parenterally, or orally, and can be effective in treating neurodegeneration, promoting neurological function, treating seizure activity and other symptoms of ASD, and can prolong life in animals including human beings having Autism Spectrum Disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.